Canada
· Delayed Price · Currency is CAD Medicure Company Description
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.
The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
| Country | Canada |
| Founded | 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Albert Friesen |
Contact Details
Address: 2-1250 Waverley Street Winnipeg, R3T 6C6 Canada | |
| Phone | 204 487 7412 |
| Website | medicure.com |
Stock Details
| Ticker Symbol | MPH |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA58469E4085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert David Friesen Ph.D. | Founder, Chief Executive Officer and Chairman of the board |
| Dr. Neil Owens Ph.D. | President and Chief Operating Officer |
| Haaris Uddin B.Com., CPA | Chief Financial Officer |
| Dr. Reuben Saba Ph.D. | Vice President of Scientific and Medical Affairs |